Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Goldman Capital Management Reduces Stake in Bacterin International Holdings Inc (BONE)

Goldman Capital Management Inc has reduced its exposure to Bacterin International Holdings Inc (NYSEMKT:BONE). In a recent filing with the Securities and Exchange Commission, the fund has revealed the reduction of its stake from 2.5 million shares reported in their latest 13F report to 1.5 million shares. Goldman Capital’s current position accounts for 2.9% of the company’s common stock.

Bacterin International Holdings Inc (BONE)

Only 3 of the hedge funds we track are also invested in Bacterin International Holdings Inc (NYSEMKT:BONE). Samuel Isaly and his fund, Orbimed Advisors, have reported in their latest 13F filing the ownership of 1.75 million shares valued at $1.17 million. During the third quarter of 2013, James E. Flynn has decreased his fund’s stake by 60%. Deerfield Management now holds 771,775 shares valued at a little over $0.5 million. Ending the list is Jim Simons. His fund, Renaissance Technologies, has initiated a position during Q3 and now owns 15,300 shares reportedly worth approximately $10,000.

Bacterin International Holdings Inc (NYSEMKT:BONE) engages in the production and sale of biologic products and has a worldwide market presence. So far this year the stock has fallen 70% to an all-time low of $0.38 per share.  The company has a market cap of $20.7 million and a beta of 2.76, which makes it a very volatile stock. Bacterin International Holdings does not pay a dividend. For the three months ended September 30, 2013, the company posted revenues of $7.9 million, a 10% year-over-year decrease, and a loss of $0.08 per share. Analysts are more optimistic about the company’s financial performance during the current quarter and expect revenues of $9.27 million and a loss per share of $0.06.

Disclosure: none

Recommended reading:

SC Fundamental Value Fund Send Letter to Transcept Pharmaceuticals Inc (TSPT); Request Special Shareholder Meeting

Cannell Capital Raises Holding in Hooper Holmes, Inc. (HH) Even Higher

Nelson Peltz, Trian Partners Reveal New Position in Ingersoll-Rand PLC (IR)’s Spin-Off Allegion PLC (ALLE)

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.